2VCJ

4,5 Diaryl Isoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.305 
  • R-Value Work: 0.221 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer.

Brough, P.A.Aherne, W.Barril, X.Borgognoni, J.Boxall, K.Cansfield, J.E.Cheung, K.M.Collins, I.Davies, N.G.M.Drysdale, M.J.Dymock, B.Eccles, S.A.Finch, H.Fink, A.Hayes, A.Howes, R.Hubbard, R.E.James, K.Jordan, A.M.Lockie, A.Martins, V.Massey, A.Matthews, T.P.Mcdonald, E.Northfield, C.J.Pearl, L.H.Prodromou, C.Ray, S.Raynaud, F.I.Roughley, S.D.Sharp, S.Y.Surgenor, A.Walmsley, D.L.Webb, P.Wood, M.Workman, P.Wright, L.

(2008) J.Med.Chem. 51: 196

  • DOI: 10.1021/jm701018h
  • Primary Citation of Related Structures:  2VCI

  • PubMed Abstract: 
  • Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent sma ...

    Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure-activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%.


    Organizational Affiliation

    Vernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, U.K. p.brough@ vernalis.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
HEAT SHOCK PROTEIN HSP 90-ALPHA
A
236Homo sapiensGene Names: HSP90AA1 (HSP90A, HSPC1, HSPCA)
Find proteins for P07900 (Homo sapiens)
Go to Gene View: HSP90AA1
Go to UniProtKB:  P07900
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
2EQ
Query on 2EQ

Download SDF File 
Download CCD File 
A
5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
C23 H24 Cl N3 O5
APGOABVITLQCKW-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
2EQIC50: 21 nM (92) BINDINGDB
2EQEC50: 83 nM (92) BINDINGDB
2EQIC50: 21 nM BINDINGMOAD
2EQIC50: 21 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.5 Å
  • R-Value Free: 0.305 
  • R-Value Work: 0.221 
  • Space Group: I 2 2 2
Unit Cell:
Length (Å)Angle (°)
a = 66.038α = 90.00
b = 89.289β = 90.00
c = 99.516γ = 90.00
Software Package:
Software NamePurpose
d*TREKdata reduction
SCALEPACKdata scaling
AMoREphasing
REFMACrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2007-12-11
    Type: Initial release
  • Version 1.1: 2011-05-08
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance